Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Neutralization serotyping of BK polyomavirus infection in kidney transplant recipients

Pastrana, DV and Brennan, DC and Çuburu, N and Storch, GA and Viscidi, RP and Randhawa, PS and Buck, CB (2012) Neutralization serotyping of BK polyomavirus infection in kidney transplant recipients. PLoS Pathogens, 8 (4). ISSN 1553-7366

Published Version
Available under License : See the attached license file.

Download (777kB) | Preview
[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)


BK polyomavirus (BKV or BKPyV) associated nephropathy affects up to 10% of kidney transplant recipients (KTRs). BKV isolates are categorized into four genotypes. It is currently unclear whether the four genotypes are also serotypes. To address this issue, we developed high-throughput serological assays based on antibody-mediated neutralization of BKV genotype I and IV reporter vectors (pseudoviruses). Neutralization-based testing of sera from mice immunized with BKV-I or BKV-IV virus-like particles (VLPs) or sera from naturally infected human subjects revealed that BKV-I specific serum antibodies are poorly neutralizing against BKV-IV and vice versa. The fact that BKV-I and BKV-IV are distinct serotypes was less evident in traditional VLP-based ELISAs. BKV-I and BKV-IV neutralization assays were used to examine BKV type-specific neutralizing antibody responses in KTRs at various time points after transplantation. At study entry, sera from 5% and 49% of KTRs showed no detectable neutralizing activity for BKV-I or BKV-IV neutralization, respectively. By one year after transplantation, all KTRs were neutralization seropositive for BKV-I, and 43% of the initially BKV-IV seronegative subjects showed evidence of acute seroconversion for BKV-IV neutralization. The results suggest a model in which BKV-IV-specific seroconversion reflects a de novo BKV-IV infection in KTRs who initially lack protective antibody responses capable of neutralizing genotype IV BKVs. If this model is correct, it suggests that pre-vaccinating prospective KTRs with a multivalent VLP-based vaccine against all BKV serotypes, or administration of BKV-neutralizing antibodies, might offer protection against graft loss or dysfunction due to BKV associated nephropathy.


Social Networking:
Share |


Item Type: Article
Status: Published
CreatorsEmailPitt UsernameORCID
Pastrana, DV
Brennan, DC
Çuburu, N
Storch, GA
Viscidi, RP
Randhawa, PSpsr@pitt.eduPSR
Buck, CB
ContributionContributors NameEmailPitt UsernameORCID
Date: 1 April 2012
Date Type: Publication
Journal or Publication Title: PLoS Pathogens
Volume: 8
Number: 4
DOI or Unique Handle: 10.1371/journal.ppat.1002650
Schools and Programs: School of Medicine > Pathology
Refereed: Yes
ISSN: 1553-7366
MeSH Headings: Animals; Antibodies, Neutralizing--blood; Antibodies, Neutralizing--immunology; Antibodies, Neutralizing--pharmacology; Antibodies, Viral; BK Virus--immunology; BK Virus--metabolism; Disease Models, Animal; Female; Humans; Kidney Diseases--immunology; Kidney Diseases--prevention & control; Kidney Transplantation; Male; Mice; Mice, Inbred BALB C; Polyomavirus Infections--blood; Polyomavirus Infections--immunology; Polyomavirus Infections--prevention & control; Time Factors; Vaccination--methods; Viral Vaccines--immunology; Viral Vaccines--pharmacology
Other ID: NLM PMC3325208
PubMed Central ID: PMC3325208
PubMed ID: 22511874
Date Deposited: 24 Sep 2012 20:26
Last Modified: 05 Feb 2019 01:55


Monthly Views for the past 3 years

Plum Analytics

Actions (login required)

View Item View Item